N1BI34.SA Neurocrine Biosciences Inc.
- Market cap
- BRL 93.0B
- P/E
- 26.1x
- P/B
- 4.65x
- ROE
- 18.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is N1BI34.SA undervalued?
Graham numberN1BI34.SA trades 132.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neurocrine Biosciences Inc. fundamental analysis
No fundamental analysis for Neurocrine Biosciences Inc. yet.
Neurocrine Biosciences Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under th…
Full company profileNeurocrine Biosciences Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neurocrine Biosciences Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 451M | 788M | 1.05B | 1.13B | 1.49B | 1.89B | 2.36B | 2.86B | 3.55B |
| Gross Profit | 446M | 781M | 1.04B | 1.12B | 1.47B | 1.85B | 2.32B | 2.81B | 3.47B |
| Operating Income | 36.9M | 227M | 328M | 208M | 179M | 251M | 571M | 619M | 678M |
| EBITDA | 56.4M | 86.0M | 148M | 138M | 265M | 416M | 640M | 667M | 766M |
| Net Income | 21.1M | 37.0M | 407M | 89.6M | 155M | 250M | 341M | 479M | 685M |
| EPS | 0.23 | 0.40 | 4.36 | 0.94 | 1.60 | 2.53 | 3.43 | 4.78 | 6.74 |
| Balance Sheet | |||||||||
| Total Assets | 993M | 1.31B | 1.73B | 2.07B | 2.37B | 3.25B | 3.72B | 4.63B | 5.36B |
| Total Liabilities | 512M | 669M | 609M | 699M | 661M | 1.02B | 1.13B | 1.38B | 1.67B |
| Shareholders' Equity | 481M | 637M | 1.13B | 1.37B | 1.71B | 2.23B | 2.59B | 3.25B | 3.69B |
| Cash & Short-term Investments | 142M | 112M | 801M | 711M | 989M | 1.03B | 1.08B | 1.48B | 332M |
| Cash Flow | |||||||||
| Operating Cash Flow | 101M | 147M | 229M | 257M | 339M | 390M | 595M | 783M | 564M |
| Capital Expenditure | 24.8M | 14.7M | 10.9M | 23.4M | 16.5M | 28.3M | 38.2M | 34.0M | 33.8M |
| Free Cash Flow | 76.6M | 137M | 218M | 233M | 323M | 362M | 557M | 749M | 531M |
| Ratios | |||||||||
| ROE | 4.4% | 5.8% | 36.2% | 6.5% | 9.0% | 11.2% | 13.2% | 14.7% | 18.5% |
| ROA | 2.1% | 2.8% | 23.5% | 4.3% | 6.5% | 7.7% | 9.2% | 10.3% | 12.8% |
| Net Profit Margin | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% | 19.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Neurocrine Biosciences Inc. dividends
Neurocrine Biosciences Inc. has not paid dividends in the last 8 fiscal years.
Who owns Neurocrine Biosciences Inc.
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 2.02B
- Free float 2.00B
Neurocrine Biosciences Inc. company profile
- Company name
- Neurocrine Biosciences Inc.
- Ticker
- N1BI34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,500
- Fiscal year end
- December
- Address
- 6027 Edgewood Bend Court, San Diego, CA, United States, 92130
- Phone
- 858 617 7600
- Website
- neurocrine.com
About Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences Inc. management
10- Mr. Kyle W. Gano Ph.D.President, CEO & Director · born 1973
- Mr. Matthew C. Abernethy CPAChief Financial Officer · born 1980
- Dr. Jude Onyia Ph.D.Chief Scientific Officer · born 1964
- Mr. Eric S. BenevichChief Commercial Officer · born 1965
- Dr. Eiry Wyn Roberts M.D.Chief Medical Officer · born 1964
- Dr. Wylie W. Vale Ph.D.Co-Founder · born 1942
- Dr. Lawrence Steinman BA, M.D., Ph.D.Co-Founder of Neurocrine · born 1948
- Mr. Aaron VosburghSenior Vice President of Finance & Accounting
- Mr. Lewis ChoiChief Information Officer
- Mr. Todd TushlaVice President of Investor Relations